WELIREGTM (belzutifan), FDA Approved, Available at Biologics by McKesson
CARY, N.C., August 20, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Merck& Co. as a specialty pharmacy provider for WELIREGTM (belzutifan), an inhibitor of hypoxia-inducible factor-2a (HIF-2a) indicated for the t... (Source: McKesson News)
Source: McKesson News - August 20, 2021 Category: Information Technology Source Type: news
McKesson to Host Investor Day on December 8, 2021
IRVING, Texas, August 16, 2021 – McKesson Corporation (NYSE:MCK) today announced that the Company will host an Investor Day on December 8, 2021 in New York City. (Source: McKesson News)
Source: McKesson News - August 16, 2021 Category: Information Technology Source Type: news
McKesson Reports Fiscal 2022 First-Quarter Results
First-Quarter Highlights, Year-over-Year: (Source: McKesson News)
Source: McKesson News - August 4, 2021 Category: Information Technology Source Type: news
REZUROCK (belumosudil) tablets, FDA Approved for Treatment of Chronic Graft-Versus-Host Disease, Available at Biologics by McKesson
CARY, N.C., July 30, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, today announced that it has been selected by Kadmon (Nasdaq: KDMN) as a specialty pharmacy provider for REZUROCK™ (belumosudil) for the treatment of adult and pediatric... (Source: McKesson News)
Source: McKesson News - July 30, 2021 Category: Information Technology Source Type: news
McKesson Raises Quarterly Dividend by 12% to $0.47 Per Share
IRVING, Texas, July 26, 2021 — The Board of Directors of
McKesson Corporation (NYSE:MCK) declared on July 23, 2021 a regular dividend of
$0.47 per share of common stock, a 12% increase from $0.42 per share in the
prior quarter. The dividend will be payable on October 1, 2021, to stockholders
of reco... (Source: McKesson News)
Source: McKesson News - July 26, 2021 Category: Information Technology Source Type: news
McKesson Corporation Announces Pricing and Upsizing of Tender Offer
IRVING, Texas, July 22, 2021 — McKesson Corporation (NYSE: MCK) (the “Company”) today announced the determination of the Full Tender Offer Consideration, as shown in the table below, for its previously announced cash tender offer to purchase up to $500,000,000 aggregate principal amount (the “Offer”... (Source: McKesson News)
Source: McKesson News - July 22, 2021 Category: Information Technology Source Type: news
McKesson Corporation Announces Early Tender Results and Intention to Increase the Tender Cap
IRVING, Texas, July 22, 2021 -- McKesson Corporation (NYSE: MCK) (the “Company”) today announced the early tender results as of the Early Tender Time (as defined below) in connection with its previously announced cash tender offer to purchase up to $500,000,000 (subject to increase, the “Tender Cap”... (Source: McKesson News)
Source: McKesson News - July 22, 2021 Category: Information Technology Source Type: news
Distributors Announce Proposed Opioid Settlement Agreement
CONSHOHOCKEN, PA, DUBLIN, OH and IRVING, TX, July 21, 2021 —AmerisourceBergen (NYSE: ABC), Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK) announced today that they have negotiated a comprehensive proposed settlement agreement which, if all conditions are satisfied, would result in the settlemen... (Source: McKesson News)
Source: McKesson News - July 21, 2021 Category: Information Technology Source Type: news
Distributors Reach Opioid Settlement with New York State
CENTRAL ISLIP, New York, July 20, 2021 —AmerisourceBergen (NYSE: ABC), Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK) announced today that they have agreed to pay up to $1.179 billion in a settlement with the State of New York and its participating subdivisions, including Nassau and Suffolk Cou... (Source: McKesson News)
Source: McKesson News - July 20, 2021 Category: Information Technology Source Type: news
McKesson Named One of the Best Places to Work for Disability Inclusion
IRVING, Texas, July 13, 2021 — For the sixth consecutive year, McKesson is honored as one of the “Best Places to Work for Disability Inclusion” by Disability Equality Index (DEI). McKesson also earned a top score of 100% for displaying best-in-class commitments to culture and leadership, accessibilit... (Source: McKesson News)
Source: McKesson News - July 13, 2021 Category: Information Technology Source Type: news
McKesson Corporation Announces Offer to Purchase $500 Million Aggregate Principal Amount of Debt
IRVING, Texas, July 8, 2021 -- McKesson Corporation (NYSE: MCK) (the “Company”) today announced the commencement of a cash tender offer to purchase up to $500,000,000 (subject to increase, the “Tender Cap”) aggregate principal amount (the “Offer”) of its outstanding 6.00% Notes due 2041 (the “6.00% ... (Source: McKesson News)
Source: McKesson News - July 8, 2021 Category: Information Technology Source Type: news
McKesson Corporation Enters Agreement to Sell Certain European Businesses to the PHOENIX Group
Transaction enhances McKesson ’s focus and commitment to future investments in strategic growth, including oncology and biopharma services, and core pharmaceutical and medical distributionAgreement includes the sale of McKesson Europe businesses in France, Italy, Ireland, Portugal, Belgium, and Slove... (Source: McKesson News)
Source: McKesson News - July 7, 2021 Category: Information Technology Source Type: news
McKesson Corporation to Announce First Quarter Fiscal 2022 Results on August 4, 2021
IRVING, Texas, June 30, 2021 —McKesson Corporation (NYSE: MCK) will release its first quarter fiscal 2022 financial results after market close on Wednesday, August 4, 2021. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financi... (Source: McKesson News)
Source: McKesson News - June 30, 2021 Category: Information Technology Source Type: news
TRUSELTIQ (infigratinib), FDA Approved for Treatment of Cholangiocarcinoma, Available at Biologics by McKesson
CARY, N.C., June 21, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by QED Therapeutics, an affiliate of BridgeBio Pharma, Inc. (BridgeBio) and Helsinn Group, as a specialty pharmacy provider for TRUSELTIQTM (infigrati... (Source: McKesson News)
Source: McKesson News - June 21, 2021 Category: Information Technology Source Type: news
LUMAKRAS (sotorasib), FDA Approved for Treatment of KRAS G12C-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer, Available at Biologics by McKesson
CARY, N.C., June 11, 2021 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Amgen Oncology as a specialty pharmacy provider for LUMAKRASTM (sotorasib) for the treatment of patients with KRAS G12C-mutated locally advanced ... (Source: McKesson News)
Source: McKesson News - June 11, 2021 Category: Information Technology Source Type: news
